Ryvu Therapeutics S.A. (WSE: RVU)

Market Cap	1.01B
Revenue (ttm)	91.18M
Net Income (ttm)	-104.14M
Shares Out	23.12M
EPS (ttm)	-4.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,288
Open	46.50
Previous Close	45.05
Day's Range	43.60 - 47.10
52-Week Range	39.50 - 67.10
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 270
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2023, Ryvu Therapeutics's revenue was 67.30 million, a decrease of -1.67% compared to the previous year's 68.44 million. Losses were -92.11 million, 9.94% more than in 2022.